lymphoma

[Aging-Us] Researchers established in vitro cultured mixed-natural killer cells (NKM) to achieve immune normalization. The in vitro cytotoxicity of NKM cells was tenfold higher than that of peripheral blood mononuclear cells

[Pharmaceutical Biology] Human hepatic carcinoma cell lines were treated with different concentrations of myristicin for 24, 48 and 72 hours. Then tetrazolium assay, flow cytometer analysis and transwell assay were performed to determine cell proliferation, apoptosis and migration/invasion, respectively.

[Stem Cell Research & Therapy] Scientists discuss and explain the most recent advances in chimeric antigen receptor (CAR) T cell-based therapies targeting acute myeloid leukemia (AML) antigens and review the results of preclinical and clinical trials.

[Science Signaling] To design CARs with a lower activation threshold, scientists compared antigen-induced pathway signaling in human T cells expressing a current CAR construct to that in cells with endogenous TCRs.

[Bone Marrow Transplantation] The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-hematopoietic cell transplantation, and chimeric antigen receptor T-cell therapy for patients with newly diagnosed and relapsed/refractory mantle cell lymphoma.

[Blood] This phase I-II study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). BV and Nivo with staggered or concurrent dosing were active and well tolerated when used as first salvage therapy in patients with r/r cHL.